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Rapid eye movement sleep behaviour disorder has been evaluated using Parkinson’s disease-related metabolic network. It is
unknown whether this disorder is itself associated with a unique metabolic network. 18F-fluorodeoxyglucose positron emission
tomography was performed in 21 patients (age 65.0  5.6 years) with idiopathic rapid eye movement sleep behaviour disorder
and 21 age/gender-matched healthy control subjects (age 62.5  7.5 years) to identify a disease-related pattern and examine its
evolution in 21 hemi-parkinsonian patients (age 62.6  5.0 years) and 16 moderate parkinsonian patients (age 56.9  12.2
years). We identified a rapid eye movement sleep behaviour disorder-related metabolic network characterized by increased
activity in pons, thalamus, medial frontal and sensorimotor areas, hippocampus, supramarginal and inferior temporal gyri, and
posterior cerebellum, with decreased activity in occipital and superior temporal regions. Compared to the healthy control
subjects, network expressions were elevated (P 5 0.0001) in the patients with this disorder and in the parkinsonian cohorts
but decreased with disease progression. Parkinson’s disease-related network activity was also elevated (P 5 0.0001) in the
patients with rapid eye movement sleep behaviour disorder but lower than in the hemi-parkinsonian cohort. Abnormal metabolic
networks may provide markers of idiopathic rapid eye movement sleep behaviour disorder to identify those at higher risk to
develop neurodegenerative parkinsonism.
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Abnormal metabolic network activity in RBD

Introduction
Rapid eye movement sleep behaviour disorder (RBD) is a parasomnia characterized by dream enactment behaviours
emerging during REM sleep and associated with a loss of
normal skeletal muscle atonia (Boeve, 2010). Abnormal neural
circuits resulting from damage to brainstem areas may have precipitated idiopathic RBD leading to the loss of motor inhibition
during rapid eye movement (REM) sleep (Boeve et al., 2007; Lu
and Saper, 2011). Idiopathic RBD is regarded as a prodromal
stage of synucleinopathies such as Parkinson’s disease, dementia
with Lewy bodies and multiple system atrophy because it often
precedes the development of motor, cognitive, neuropsychiatric
and autonomic features of these syndromes by years or decades
(Iranzo et al., 2006; Postuma et al., 2009; Claassen et al., 2010;
Schenck et al., 2013). Functional neuroimaging studies with
Single Photon Emission Computed Tomography (SPECT) or
PET provided further support with reduced nigrostriatal dopaminergic activity (Eisensehr et al., 2000; Iranzo et al., 2011),
decreased cardiac adrenergic activity (Miyamoto et al., 2006;
Fujishiro et al., 2010) and impaired brain perfusion (Hanyu
et al., 2011; Vendette et al., 2011) found in patients with idiopathic RBD.
Metabolic imaging with FDG PET and spatial covariance analysis has provided valuable information concerning the abnormal
regional brain function underlying neurodegenerative disorders
(Eidelberg, 2009). Abnormal metabolic brain networks have
been identified for Parkinson’s disease, multiple system atrophy
and progressive supranuclear palsy for accurate classification of
these parkinsonian disorders at the single-patient level, even at
early disease stages (Ma et al., 2007; Eckert et al., 2008; Tang
et al., 2010). We have also identified a Parkinson’s diseaserelated covariance pattern (PDRP) in a Chinese cohort (Wu
et al., 2013) that closely resembled the original topography identified in an analogous North American cohort (Niethammer and
Eidelberg, 2012).
Abnormal changes in PDRP expression have recently been reported in two idiopathic RBD cohorts and, on an individual basis,
higher baseline expression was associated with a greater likelihood
of developing Parkinson’s disease or dementia with Lewy bodies
(Holtbernd et al., 2014). It is not known, however, whether idiopathic RBD is itself associated with a unique metabolic topography
that would evolve before symptom onset. We sought to identify a
RBD-related covariance pattern (RBDRP) and determined its relationships with concurrent PDRP measurements using our networkbased algorithm (Ma et al., 2007; Spetsieris et al., 2013). We also
assessed the evolution of these network expressions in patients
with idiopathic RBD and in patients with very early and moderate
Parkinson’s disease.

Materials and methods
Subjects
For identification of RBDRP, 21 patients with idiopathic RBD [male/female: 17/4, age: 65.0  5.6 (mean  standard deviation, SD) years]
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and 21 gender/age-matched healthy control subjects (male/female:
17/4, age: 62.5  7.5 years) were recruited from Huashan Hospital
for 18F-Fluorodeoxyglucose (FDG) PET imaging (Cohort A).
Diagnosis of idiopathic RBD was made by sleep medicine experts
(H.Y. and Y.D.) requiring a history of dream-enacting behaviours
and video-polysomnographic demonstration of either increased EMG
activity or abnormal behaviours during REM sleep (Boeve, 2010).
Detailed polysomnographic procedures are included in the online
Supplementary material.
For prospective validation of RBDRP network expression we
included Cohort B with 15 patients with idiopathic RBD (male/
female: 12/3, age: 65.5  6.0 years) and 15 gender/age-matched
healthy control subjects (male/female: 10/5, age: 60.5  7.6 years).
This idiopathic RBD group comprised nine patients from Cohort A who
were scanned again at 1 year (male/female: 7/2, age: 65.2  6.9
years) and six newly recruited subjects with idiopathic RBD (male/
female: 5/1, age: 66.0  5.0 years). Clinical and polysomnographic
parameters did not differ significantly between the patients with idiopathic RBD in Cohorts A and B (Table 1).
We also included Cohort C with 21 age-matched patients with
hemi-Parkinson’s disease (male/female: 12/9, age: 62.6  5.0 years,
Hoehn and Yahr 1) and 16 patients with moderate Parkinson’s disease
(male/female: 5/11, age: 56.9  12.2 years, Hoehn and Yahr:
2.5  0.5, range 2–3) to assess the correlations between the RBDRP
and PDRP networks. All normal and parkinsonian subjects were recruited as described previously (Wu et al., 2013).
Ethical permission for the study was obtained from the Institutional
Review Board of Huashan Hospital. Written consent was obtained
from each subject after detailed explanation of the procedures.

PET imaging and processing
The imaging procedure and the data preprocessing were performed as
described in detail previously (Wu et al., 2013). Briefly, FDG PET
images of relative glucose metabolism were acquired with a Siemens
Biograph 64 PET/CT (Siemens) and spatially normalized into a standard brain space by statistical parametric mapping software (SPM5;
Institute of Neurology, London, UK).

Network analysis and prospective
comparisons
RBDRP was identified from the combination of idiopathic RBD and
control subjects in Cohort A by an automated voxel-based network
analysis over the whole brain (Ma et al., 2007; Spetsieris et al., 2013).
This was done within a grey matter mask defined with all FDG PET
images by applying scaled subprofile model/principal component analysis (SSM/PCA; available on http://www.feinsteinneuroscience.org at
the Centre for Neuroscience, the Feinstein Institute for Medical
Research, Manhasset, NY, USA). The reliability of the resulting topography was evaluated by using a bootstrapping resample scheme
described previously (Habeck et al., 2008; Peng et al., 2014).
The RBDRP was compared topographically to the PDRP (Wu
et al., 2013) using volume- or voxel-wise correlations over the
whole brain. The expressions of RBDRP or PDRP were quantified in
all subjects with a voxel-based algorithm (Ma et al., 2007; Spetsieris
et al., 2013). The network expression was Z-transformed using subject
scores of the controls in the corresponding derivation cohort for each
network.
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Table 1 Clinical characteristics and polysomnographic
measures in patients with idiopathic RBD

Sex (male/female)
Age (years)
Age at onset of RBD (years)
RBD duration (years)
UPDRS III
Body mass index (kg/m2)
Polysomnographic data
Total sleep time (min)
Sleep efficiency (%)
Sleep onset latency(min)
REM sleep latency(min)
Non-REM sleep 1 (%)
Non-REM sleep 2 (%)
Non-REM sleep 3 (%)
REM sleep (%)
Microarousals index
Phasic EMG activity index/chin
Tonic EMG activity index /chin
Phasic EMG activity index /legs
Tonic EMG activity index /legs
Patients with either abnormal
phasic or tonic chin EMG
activity in REM sleep (%)
Apnoea-hypopnoea index
Mean SaO2

Cohort A

Cohort B

17/4
65.0  5.6
59.3  6.9
5.7  3.5
2.4  2.1
23.8  2.7

12/3
65.5  6.0
60.1  7.6
5.5  4.0
2.8  1.9
23.8  2.5

329.2  47.0
74.9  9.4
26.7  32.2
81.4  38.0
17.2  8.7
46.2  9.2
19.5  8.2
17.2  5.1
15.2  7.4
17.9  9.8
16.0  11.9
12.7  7.1
8.1  6.3
10 (47.6%)

325.3  39.5
73.5  10.7
21.1  24.9
96.1  37.2
17.1  9.4
47.7  7.5
18.0  8.5
17.1  5.8
16.1  4.9
17.5  8.5
17.8  16.4
13.5  8.2
8.0  7.3
7 (46.7%)

3.0  4.0
94.5  0.9

3.8  2.7
94.5  1.2

Values are given as means  SD.

Statistical analysis
Differences in network expression between patients and normal control subjects were assessed by Student’s t-tests with their diagnostic
power for group discrimination evaluated by receiver operating characteristic analysis. One-way ANOVA was performed for each network
measure across the subject groups with between-group differences
assessed using post hoc Tukey’s HSD tests. Group  network activity
interaction was evaluated by two-way ANOVA to determine whether
any differences exist between changes for each of these network
measures over the subject groups. Correlations between RBDRP and
PDRP expressions as well as those with clinical measures in different
subject groups were separately assessed by computing Pearson correlation coefficients. All analyses were performed using SPSS software
(SPSS Inc.) and considered significant for P 5 0.05.

Results
RBD-related pattern identification and
disease discrimination
In Cohort A, the RBDRP was identified as the first principal component accounting for 14.0% of subject  voxel variance. The
pattern was characterized by increased metabolic activity in
pons, thalamus, precentral gyrus, supplementary motor area,
medial frontal gyrus, hippocampus/parahippocampal gyrus,

supramarginal and inferior temporal gyrus, and posterior cerebellar
tonsil, associated with decreased metabolic activity in occipital regions, midbrain (red nucleus) and superior/middle temporal gyrus
(Fig. 1A; Supplementary Table 1). RBDRP expression was abnormally elevated (P 5 0.0001) in the patients with idiopathic RBD
compared with the control subjects (Fig. 1B) and significantly discriminated (P 5 0.0001) the subject groups, with an area under
the curve of 0.989  0.013 and a sensitivity of 95.2% and a specificity of 95.2%.

Comparisons between spatial
topographies of RBD- and Parkinson’s
disease-related patterns
Both RBDRP and PDRP showed varying degrees of overlap in
several brain areas including the thalamus, sensorimotor cortices
and occipital regions (Figs 1A and 2A). Their region-weights correlated significantly with each other using both volumetric
(r = 0.634, P 5 0.002) and voxelized (r = 0.680; P 5 0.0001)
analyses.

RBD-related pattern expressions in
patients with Parkinson’s disease
RBDRP expressions in different patient cohorts were presented in
Table 2 and Fig. 1B. RBDRP activity differed significantly among
the multiple subject groups [F(3,75) = 51; F(3,63) = 32,
P 5 0.0001; one-way ANOVA across Cohorts A and C or B and
C, respectively]. RBDRP expression in the patients with idiopathic
RBD was similarly elevated (P 5 0.0001) relative to the controls in
Cohort A/B. RBDRP scores were also elevated (P 5 0.0001) in the
hemi-parkinsonian patients but slightly lower (P 5 0.18) than
these patients with idiopathic RBD. However, these scores
decreased significantly in the moderate parkinsonian patients compared to the idiopathic RBD patients in Cohort A/B (P = 0.032/
0.014). RBDRP scores did not differ between the two parkinsonian
groups (P 5 0.22).

Parkinson’s disease-related pattern
expressions in patients with idiopathic
RBD
PDRP expressions in different patient cohorts were presented in
Table 2 and Fig. 2B. PDRP activity differed significantly among the
multiple subject groups [F(3,75) = 42; F(3,63) = 21, P 5 0.0001;
one-way ANOVA across Cohorts A and C or B and C, respectively]. PDRP scores in the idiopathic RBD patients in Cohort A/B
were similarly elevated (P 5 0.0001) relative to the controls,
decreased not significantly (P 5 0.74) versus the hemi-parkinsonian patients but significantly (P = 0.001/0.047) versus the moderate parkinsonian patients. PDRP scores increased significantly
(P = 0.014/0.035) comparing the moderate to the hemi-parkinsonian groups.

Abnormal metabolic network activity in RBD
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Figure 1 (A) RBDRP identified by network analysis of FDG PET scans from 21 patients with idiopathic RBD and 21 age-matched normal
controls in Cohort A. This spatial covariance pattern was characterized by relative increases in sensorimotor, superior frontal, cingulate,
thalamic, pontine, and cerebellar metabolism, associated with decreases in occipital, midbrain and superior temporal metabolism. The
pattern was overlaid on a standard MRI brain template to display voxels that were reliable at P 5 0.01 based on the bootstrapping
algorithm. Voxels with positive region weights (metabolic increases) are colour-coded red; those with negative region weights (metabolic
decreases) are colour-coded blue. (B) RBDRP expressions (subject scores) were increased in the patients with idiopathic RBD relative to the
normal subjects in Cohort A as well as the patients with moderate Parkinson’s disease in Cohort C. These scores were also elevated when
compared to those in the hemi-parkinsonian patients in Cohort C but did not reach significance. Subject scores of the parkinsonian patients
in Cohort C were both elevated (P 5 0.0001; post hoc tests) versus the normal controls. The error bars represent standard errors of the
mean. NL = normal control; HY = Hoehn and Yahr; SMA = supplementary motor area.

Figure 2 (A) PDRP identified by network analysis of FDG PET scans from 33 patients with Parkinson’s disease and 33 age-matched
normal control subjects (Wu et al., 2013). This spatial covariance pattern was characterized by relative increases in sensorimotor,
pallidothalamic, pontine, and cerebellar metabolism, associated with decreases in premotor and posterior parietal-occipital metabolism.
The pattern was overlaid onto a standard MRI brain template to display voxels that were reliable at P 5 0.001 based on the bootstrapping
algorithm. Voxels with positive region weights (metabolic increases) are colour coded red; those with negative region weights (metabolic
decreases) are colour coded blue. (B) PDRP expressions (subject scores) were increased in the patients with idiopathic RBD relative to the
normal subjects in Cohort A but decreased relative to the moderate parkinsonian patients in Cohort C. These scores were also decreased
slightly but not significantly when compared to the hemi-parkinsonian patients in Cohort C. Subject scores of the parkinonian patients in
Cohort C were both elevated (P 5 0.0001; post hoc tests) versus the normal controls. The error bars represent standard errors of the
mean. GP = globus pallidus; PU = putamen; NL = normal control; HY = Hoehn and Yahr; SMA = supplementary motor area;
SMC = sensorimotor cortex.
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Table 2 Network expressions in normal controls, patients
with idiopathic RBD and Parkinson’s disease

Cohort A
Normal control
Idiopathic RBD
Cohort B
Normal control
Idiopathic RBD
Cohort C
Parkinson’s disease
(Hoehn and Yahr 1)
Parkinson’s disease
(Hoehn and Yahr 2–3)

n

RBDRP scores

PDRP scores

21
21

0.00  1.00
6.31  2.23

0.08  0.72
2.25  0.97

15
15

1.03  1.48
6.96  1.54

0.47  0.95
2.52  1.22

21

5.72  1.59

2.57  0.93

16

4.97  2.38

3.60  1.38

PDRP expression in the patients with idiopathic RBD was lower or
comparable to the hemi-parkinsonian patients, in agreement with
the recent report (Holtbernd et al., 2014).
We have also observed unique differences between RBDRP and
PRDP. Firstly, the RBDRP included several specific regions such as
hippocampus and midbrain, but excluded the putamen and pallidum (Figs 1A and 2A). Secondly, RBDRP activity declined while
PRDP activity increased steadily in patients with idiopathic RBD,
hemi- and moderate Parkinson’s disease, given the elevation of
both network activities in each of these patient cohorts relative
to the controls. Thirdly, not surprisingly, subject scores of PDRP
(not RBDRP) correlated moderately with clinical motor ratings in
the combined patient cohort of very early to moderate Parkinson’s
disease.

Values are given as means  SD.

Relationships with dementia with Lewy
bodies or multiple system atrophy
Comparisons of network activities and
clinical correlations in patients with
idiopathic RBD and Parkinson’s disease
RBDPR and PDRP scores disclosed an effect of interaction across
the multiple subject groups (F = 9.4/9.3, P = 0.003; two-way
ANOVA across Cohorts A and C or B and C, respectively).
RBDRP and PDRP scores correlated in the idiopathic RBD patients
in Cohort A (r = 0.710, P 5 0.0001) and in the parkinsonian
cohort (r = 0.387, P = 0.018). UPDRS motor ratings correlated
with PDRP (r = 0.481, P = 0.003) but not RBDRP (r = 0.14,
P = 0.41) scores in the parkinsonian cohort. Moreover, neither
network scores correlated with clinical and polysomnographic parameters in patients with idiopathic RBD.

Discussion
This report describes the first study to identify a characteristic
metabolic brain network (i.e. RBDRP) with FDG PET in an idiopathic RBD population. RBDRP featured a highly symmetrical topography suggesting the existence of a widely-distributed brain
network of abnormal metabolic activity underlying this disorder.
RBDRP expression accurately discriminated patients with RBD
from normal control subjects in both derivation and validation
samples. Moreover, RBDRP activity decreased but PDRP activity
increased in early to moderate parkinsonian patients compared to
patients with idiopathic RBD.

Comparisons of brain network
characteristics associated with
idiopathic RBD and Parkinson’s disease
We have noted that RBDRP and PRDP share some similarities.
Firstly, the two topographic patterns showed moderate overlap.
Secondly, both RBDRP and PDRP expressions were elevated and
correlated with each other in patients with RBD. Thirdly, elevated

Occipital and parietotemporal hypometabolism evident in both
RBDRP and PDRP is also a finding frequently seen on FDG PET
and perfusion SPECT in patients with probable dementia with
Lewy bodies (Mosconi et al., 2008; Inui et al., 2014). Thus, a
PDRP-like network may underlie dementia with Lewy bodies to
a large degree and an elevated PDRP activity in idiopathic RBD
may also point to the subsequent development of this disorder
with disease progression (Holtbernd et al., 2014). Of the 17 subjects with idiopathic RBD followed clinically in that study, eight
(47%) who had similarly elevated PDRP scores at baseline were
diagnosed with Parkinson’s disease or dementia with Lewy bodies
after 4.6  2.5 years, in line with the estimated risk in the same
period (Iranzo et al., 2006; Postuma et al., 2009). That said, it
may still be necessary to assess other likely clinical outcomes using
different spatial covariance patterns associated with Parkinson’s
disease-related cognitive impairment (Huang et al., 2007) and
multiple system atrophy (Eckert et al., 2008; Teune et al., 2013).

Evolving metabolic brain networks and
activities in patients with idiopathic
RBD with disease progression
RBDRP depicts an insightful spatial covariance map for describing
intrinsic connectivity between regional abnormalities and related
pathways. The topography of RBDRP includes increased metabolic
activity in the pons, thalamus and hippocampus, consistent with
regional abnormalities measured with FDG PET and perfusion
SPECT in several idiopathic RBD cohorts (Vendette et al., 2011;
Dang-Vu et al., 2012; Holtbernd et al., 2014). Notably, in addition to increases in the putamen, the latter studies also found that
increased metabolism and perfusion in the pons and/or hippocampus at baseline were predictive of the eventual onset of
Parkinson’s disease or dementia with Lewy bodies in 3–5 years.
Overall, the present study has revealed several dysfunctional
neural circuits linking brainstem, midbrain, cerebellum, thalamus
and fronto-occipital cortices, in line with the pathophysiology of
idiopathic RBD and related disorders (Boeve et al., 2007; Lu and
Saper, 2011; Del Tredici and Braak, 2013).

Abnormal metabolic network activity in RBD
The findings that RBDRP activity decreased but PDRP activity
increased in patients with advancing Parkinson’s disease compared
to patients with idiopathic RBD (Figs 1B and 2B) suggest that
RBDRP is perhaps relevant only for prodromal RBD cases and
likely to break down with disease progression. This is supported
by the lack of any correlations between RBDRP activity and clinical
motor ratings in either RBD or parkinsonian cohort. Collectively
these results pointed out the hypothesis of an evolving abnormal
metabolic network with disease progression: from a RBDRP at very
early stages (i.e. idiopathic RBD) to a PDRP at later stages when a
neurodegenerative process is really advanced to that of
Parkinson’s disease. This process is expected to coincide with the
appearance in the resulting network of covarying subcortical
regions in basal ganglia (i.e. putamen) with increased metabolic
activity. This is a hypothesis to be validated by long-term clinical
and imaging studies.
This study has some limitations. First, brain metabolism has been
assessed not in REM sleep when the abnormal behaviour occurred.
However, as currently reported in wake resting state, an increased
perfusion in supplementary motor area during a RBD episode in a
severe patient affected with multiple system atrophy was also reported in a SPECT study (Dauvilliers et al., 2011). Second, no
absolute brain glucose metabolism was quantified to adequately
propose a pathophysiological explanation on the network architecture underlying idiopathic RBD. Nevertheless, this study did disclose an abnormal metabolic network implying a specific brain
circuitry. Third, elevated RBDRP/PDRP expressions in the patients
with idiopathic RBD relative to the control subjects were replicated
but not in a truly independent cohort. Regardless this result at
least demonstrates that these metabolic network activities are
highly reproducible across different idiopathic RBD subjects or
metabolic images. Finally, idiopathic RBD was diagnosed by a
visual scoring method with excellent sensitivity and specificity for
both phasic and tonic chin EMG measures. However, despite a
typical history of dream-enacting behaviours in all patients with
idiopathic RBD, only 48% of them had abnormal REM sleep
without atonia with the remainder presenting complex movements
during REM sleep.
In conclusion, we have reported the first identification of RBDRP
with FDG PET, which may be useful in differentiating patients with
idiopathic RBD from normal controls and in revealing similarities
and unique differences with PDRP. The close association of neuropathological processing between RBD and Parkinson’s disease suggests that idiopathic RBD is indeed a prodromal phase of
Parkinson’s disease along a wide spectrum of disease progression.
Further prospective studies are necessary to determine the relationships between baseline measurements in network expression
and eventual clinical outcomes of idiopathic RBD patients.
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